Both doses of MK-1439 monotherapy tested in the study produced similar > 1 log10 decreases in HIV-1 RNA over 7 days.
In treatment-naive patients with CCR5-tropic HIV infection, combination of cenicriviroc plus tenofovir DF/emtricitabine associated with generally similar virologic responses at Week 24 compared with efavirenz plus tenofovir DF/emtricitabine, with fewer discontinuations due to adverse events.
Randomized noninferiority study in patients with PI, NNRTI, and NRTI experience and/or viral resistance suggests that NRTIs may be safely omitted from a new optimized regimen without compromising efficacy.
In interim analysis, lower rates of virologic failure and integrase inhibitor resistance in dolutegravir-treated patients vs those receiving raltegravir, with similar safety profile.
Study results validate WHO-recommended second-line therapy of boosted PI plus NRTIs and lend support to a potential new second-line strategy using NRTI-sparing raltegravir-based regimen.
Despite high retention and high self-reported adherence, drug levels low in all 3 study arms from outset of trial, and no difference in rates of HIV acquisition compared with placebo.
HIV reservoir size declined in patients who received antiretroviral therapy, with most patients achieving undetectable HIV DNA levels within 1 year.
Possible functional cure described in 26-month-old child, who had detectable plasma HIV-1 RNA and PBMC HIV-1 DNA at birth to mother who did not receive ART during pregnancy, was treated with triple-therapy ART by 31 hours after birth and discontinued ART at age 18 months.
Although sustained activation of HIV transcription was observed in CD4+ T cells, vorinostat did not induce any changes in HIV DNA, suggesting that additional strategies need to be explored for elimination of latently infected cells.
Few differences reported from subset analyses of 2 phase III trials including efficacy and discontinuation rates of dolutegravir-based regimens compared with efavirenz- and raltegravir-based regimens
More than one third of patients in cohort did not have genotypic resistance tests before antiretroviral therapy in most recent period.
In this large, prospective cohort study, exposure to efavirenz in the first trimester was associated with an increased risk of neurologic birth defects, and exposure to zidovudine was associated with an increased risk of congenital heart defects.
Data suggest that racial disparities in HIV incidence among MSM may be explained by partner or other susceptibility factors but not by individual risk behaviors or knowledge of partner’s serostatus.
Similar high rates of virologic suppression through Week 24 in each arm, but serum creatinine increases and BMD decreases were smaller in the tenofovir alafenamide arm than in the tenofovir DF arm.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.